Company
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Product Overview
AR-301 (Salvecin
®
)
AR-320 (Suvratoxumab)
AR-501 (Panaecin
™
)
AR-712 (COVID-19 mAb)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin
®
)
AR-101 (Aerumab
™
)
AR-201
TECHNOLOGY
Technology Overview
APEX
TM
MabIgX
®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Welcome
Corporate Governance
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Interactive Chart
Investment Calculator
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor alerts
Investor Inquiries
Contact Us
Contact Us
Careers
Company
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Product Overview
AR-301 (Tosatoxumab)
AR-320 (Suvratoxumab)
AR-501 (Panaecin
™
)
AR-712 (COVID-19 mAb)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin
®
)
AR-101 (Aerumab
TM
)
AR-201
TECHNOLOGY
Overview
MabIgX
®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Welcome
Corporate Governance
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Interactive Chart
Investment Calculator
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor alerts
Investor Inquiries
Contact Us
Contact Us
Careers
Search:
Investors
H.C. Wainwright 22nd Annual Global Investment Conference
Tuesday, September 15, 2020
3:30pm EDT
